close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

181.69 +1.15 (+0.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. 
Via Investor's Business Daily
Topics Artificial Intelligence
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
From Natera, Inc.
Via Business Wire
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
From Natera, Inc.
Via Business Wire
Analyst Scoreboard: 9 Ratings For Natera
 
Via Benzinga
Peering Into Natera's Recent Short Interest
 
Via Benzinga
Peeling Back The Layers: Exploring Natera Through Analyst Insights
 
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Natera
 
Via Benzinga
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
From Natera, Inc.
Via Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The recent stock market dip provided some discounts. 
Via The Motley Fool
Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Top 10 best performing large-cap stocks last week: Shopify, Palantir, Axon, Fortinet, Trade Desk, Natera, SharkNinja, Zillow, Aspen Tech, Uber. 
Via Benzinga
NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q2 2024
NTRA stock results show that Natera beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
(NTRA) - Analyzing Natera's Short Interest
 
Via Benzinga
Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years
 
Via Benzinga
Natera Reports Second Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Natera, Inc.
Via Business Wire
Natera to Report its Second Quarter 2024 Results on August 8, 2024
From Natera, Inc.
Via Business Wire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today
 
Via Benzinga
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,400 Today
 
Via Benzinga
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
From Natera, Inc.
Via Business Wire
Breaking Down Natera: 10 Analysts Share Their Views
 
Via Benzinga
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
From Natera, Inc.
Via Business Wire
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
Via MarketBeat
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
From Natera, Inc.
Via Business Wire
Amazon, Natera And A Financial Stock: CNBC's 'Final Trades'
The recommendation comes after a former Amazon employee accused the Seattle-based company of selling technology to Russia. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today